<p>Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 獲取免費報告）在週一的交易中上漲了 0.3%。該股票最高交易價為 15.28 美元，最後交易價為 15.04 美元。交易期間大約有 12,602 股成交，較平均每日成交量 45,161 股下降了 72%。該股票此前收盤價為 15.00 美元。</p>
<p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析師評級上調與下調</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat.com 的數據，該股票目前的共識評級為 “賣出”。</p>
<p><strong>閲讀我們對 COEP 的最新分析</strong></p>
<h2>Coeptis Therapeutics 股票表現</h2>
<p>該公司的債務與股本比率為 0.02，速動比率為 0.83，流動比率為 0.83。該公司的 50 日移動平均價格為 14.60 美元，200 日移動平均價格為 11.37 美元。該公司的市值為 7249 萬美元，市盈率為-4.59，貝塔值為-0.49。</p>
<p>Coeptis Therapeutics（納斯達克代碼：COEP - 獲取免費報告）最後一次公佈季度財報是在 8 月 14 日星期四。該公司報告的每股收益（EPS）為-1.17 美元。該季度的營業收入為 20 萬美元。</p>
<h2>Coeptis Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症（包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病）的細胞治療；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同類型的腫瘤，包括血液惡性腫瘤和實體腫瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Coeptis Therapeutics</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>增長選擇：3 只低成本股票可能會翻倍</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>這 3 只被打壓的股票準備反彈嗎？</li>
<li>如何投資小盤股</li>
<li>特朗普引發的量子股票反彈是否有持續性？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
<p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Coeptis Therapeutics 並不在名單上。</p>
<p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

COEP

<p>Coeptis Therapeutics（納斯達克代碼：COEP）股價上漲 0.3%，交易價格為 15.04 美元，最高達到 15.28 美元。交易量較平均水平下降 72%，共交易了 12,602 股。分析師維持一致的 “賣出” 評級，Weiss Ratings 重申 “賣出（e+）” 評級。該公司報告的季度每股收益為（1.17 美元），收入為 20 萬美元。Coeptis 專注於開發用於癌症治療的細胞治療平台，市值為 7249 萬美元，債務與股本比率為 0.02</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report) rose 0.3% during trading on Monday . The stock traded as high as $15.28 and last traded at $15.04. Approximately 12,602 shares changed hands during trading, a decline of 72% from the average daily volume of 45,161 shares. The stock had previously closed at $15.00.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.（納斯達克代碼：COEP - 獲取免費報告）在週一的交易中上漲了 0.3%。該股票最高交易價為 15.28 美元，最後交易價為 15.04 美元。交易期間大約有 12,602 股成交，較平均每日成交量 45,161 股下降了 72%。該股票此前收盤價為 15.00 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Coeptis Therapeutics 股票的 “賣出（e+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat.com 的數據，該股票目前的共識評級為 “賣出”。</p>
</div><p><strong>Read Our Latest Analysis on COEP</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 COEP 的最新分析</strong></p>
</div><h2>Coeptis Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.83 and a current ratio of 0.83. The company has a 50 day moving average price of $14.60 and a 200 day moving average price of $11.37. The company has a market capitalization of $72.49 million, a price-to-earnings ratio of -4.59 and a beta of -0.49.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.02，速動比率為 0.83，流動比率為 0.83。該公司的 50 日移動平均價格為 14.60 美元，200 日移動平均價格為 11.37 美元。該公司的市值為 7249 萬美元，市盈率為-4.59，貝塔值為-0.49。</p>
</div><p>Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share (EPS) for the quarter. The business had revenue of $0.20 million during the quarter.</p>
<div class="lb-trans"><p>Coeptis Therapeutics（納斯達克代碼：COEP - 獲取免費報告）最後一次公佈季度財報是在 8 月 14 日星期四。該公司報告的每股收益（EPS）為-1.17 美元。該季度的營業收入為 20 萬美元。</p>
</div><h2>Coeptis Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物製藥公司，開發針對癌症患者的細胞治療平台。其產品組合包括 CD38-GEAR-NK，一種用於治療與 CD38 相關的癌症（包括多發性骨髓瘤、慢性淋巴細胞白血病和急性髓性白血病）的細胞治療；SNAP-CAR，一種與標記的腫瘤特異性抗體共同管理的 CAR T 細胞治療平台，可能針對不同類型的腫瘤，包括血液惡性腫瘤和實體腫瘤；以及 CD38-Diagnostic，一種體外篩查工具，用於分析癌症患者是否可能適合接受抗 CD38 單克隆抗體治療。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Are These 3 Beaten-Down Stocks Ready to Rebound?</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Does the Trump-Induced Quantum Stock Rally Have Legs?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Coeptis Therapeutics</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>增長選擇：3 只低成本股票可能會翻倍</li>
<li>如何繪製斐波那契價格拐點水平</li>
<li>這 3 只被打壓的股票準備反彈嗎？</li>
<li>如何投資小盤股</li>
<li>特朗普引發的量子股票反彈是否有持續性？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Coeptis Therapeutics 嗎？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Coeptis Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Coeptis Therapeutics 並不在名單上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Coeptis Therapeutics 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Coeptis Therapeutics (NASDAQ:COEP) 的股價上漲了 0.3% - 以下是原因